HIV/AIDS nursing: assessment, interventions, and NCLEX review

HIV (human immunodeficiency virus) progressively destroys CD4+ T lymphocytes — the immune cells that coordinate the body’s response to infection — eventually producing a state of profound immunodeficiency known as AIDS (acquired immunodeficiency syndrome). Without antiretroviral therapy (ART), most people living with HIV progress to AIDS within 10 years. With modern ART, people with HIV can achieve a near-normal life expectancy, maintain an undetectable viral load, and pose no risk of sexual transmission to partners. For nurses, HIV competency spans infection control, pharmacology, opportunistic infection (OI) surveillance, adherence support, and patient education. CD4 count and viral load are the two metrics that drive virtually every clinical decision. This reference covers pathophysiology through NCLEX review and is the fourth article in the infectious disease cluster, alongside the TB nursing reference, MRSA nursing reference, and C. diff nursing reference.

HIV/AIDS at a glance

Pathophysiology

HIV structure and tropism

HIV is a single-stranded RNA retrovirus that carries reverse transcriptase — an enzyme that converts its RNA genome into DNA, which is then integrated into the host cell’s chromosomes. HIV primarily targets cells expressing the CD4 surface receptor: CD4+ T helper lymphocytes, monocytes, macrophages, and dendritic cells. Entry requires the CD4 receptor plus a co-receptor — CCR5 (used by R5-tropic strains, predominant in early infection) or CXCR4 (used by X4-tropic strains, associated with later-stage disease and faster CD4 decline).

HIV lifecycle (relevant to drug targets)

Understanding the lifecycle clarifies why multiple drug classes are needed and which step each drug class interrupts:

1. Attachment — HIV gp120 binds CD4 receptor; co-receptor binding follows (CCR5/CXCR4)
2. Fusion — gp41 inserts into host cell membrane, fusing virus and cell (target: fusion inhibitors such as enfuvirtide)
3. Reverse transcription — viral RNA converted to DNA by reverse transcriptase (target: NRTIs and NNRTIs)
4. Integration — viral DNA integrates into host chromosome via integrase enzyme (target: integrase strand transfer inhibitors/INSTIs)
5. Transcription and translation — host machinery transcribes viral DNA into new viral RNA and proteins
6. Protease cleavage — HIV protease cleaves precursor polyproteins into functional proteins (target: protease inhibitors/PIs)
7. Budding and maturation — new virions assemble at the cell membrane and bud off as infectious particles

CD4+ T-cell depletion and immune dysfunction

In primary HIV infection, viral load spikes to extremely high levels (sometimes >1 million copies/mL) as the virus replicates unchecked. CD4 count falls sharply in the first weeks, then partially recovers as the immune response develops — but never to pre-infection baseline. A low-level viral “set point” is established. Without treatment, CD4 count declines at approximately 50–100 cells/mm³ per year as chronic immune activation and ongoing viral replication destroy CD4+ T cells faster than they can be replaced.

CD4+ T cells are essential for activating macrophages, cytotoxic CD8+ T cells, and B cells. As their numbers fall, the capacity to mount effective responses against intracellular pathogens — fungi, mycobacteria, herpesviruses, protozoa — deteriorates. This is why specific opportunistic infections cluster at predictable CD4 thresholds.

AIDS: the definition in practice

AIDS is diagnosed when a person with HIV meets either of two criteria (per CDC):

• CD4 count falls below 200 cells/mm³ (normal = 500–1,500 cells/mm³), OR
• An AIDS-defining illness develops, regardless of CD4 count

The CD4 percentage (CD4 cells as a fraction of total lymphocytes) is sometimes more reliable than the absolute count in patients with lymphopenia. A CD4 percentage below 14% corresponds roughly to an absolute CD4 count below 200.

Clinical staging

WHO clinical stages and CD4 thresholds

Clinical presentation

Acute HIV syndrome (primary infection)

Two to four weeks after initial exposure, approximately 50–90% of people experience an acute retroviral syndrome — often called the “mononucleosis-like” illness:

• Fever (most common — present in >80%)
• Lymphadenopathy — cervical, axillary, inguinal
• Pharyngitis — may be severe
• Diffuse maculopapular rash — trunk and face, often non-pruritic
• Myalgia and arthralgia
• Headache, photophobia — aseptic meningitis in some patients
• Oral or genital ulcers

This syndrome is self-limiting over 2–4 weeks. Because it resembles many common viral illnesses, acute HIV is frequently missed without a high index of clinical suspicion and specific testing. Viral load is extremely high during this period (>100,000 copies/mL is common), making it a key window for transmission.

Chronic HIV (clinical latency phase)

After acute infection resolves, most people enter a clinically latent phase lasting years to over a decade without ART. The person may feel well, but HIV is continuously replicating, CD4 cells are being destroyed, and the person is infectious. Persistent generalized lymphadenopathy (PGL) — enlarged lymph nodes in two or more non-contiguous sites for >3 months without other explanation — may be present. Without treatment, the median time to AIDS is approximately 10 years.

AIDS-defining illnesses

When CD4 falls below 200 cells/mm³ or severe immunodeficiency permits, AIDS-defining illnesses emerge. Nurses must recognize the common presentations and CD4 threshold at which each is expected:

Diagnosis and monitoring

HIV testing: the 4th-generation Ag/Ab combination assay

The preferred initial test is the 4th-generation combination immunoassay (Ag/Ab combo), which simultaneously detects:

• HIV-1 and HIV-2 antibodies (IgG and IgM)
• HIV-1 p24 antigen — a viral capsid protein detectable before antibodies appear

This dual detection reduces the window period (the time between infection and a reliable positive test) to 18–45 days, compared with 6–12 weeks for older antibody-only tests. A reactive 4th-generation result is followed by an HIV-1/HIV-2 antibody differentiation immunoassay for confirmation. If the differentiation assay is negative or indeterminate, an HIV-1 nucleic acid test (NAT/viral load) is performed to resolve the discordance.

Previous generation tests (3rd-generation antibody-only tests) required the full 3-month window period before reliable negative results, and older Western blot confirmatory tests, while specific, had lower sensitivity for early infections — this is why 3rd-generation testing is now considered suboptimal.

Key monitoring parameters

Nursing assessment

Admission priorities

1. Vital signs and oxygen saturation — PCP and other respiratory OIs cause hypoxia that may precede obvious dyspnea
2. CD4 count and viral load (current and nadir) — stratifies OI risk immediately
3. Current ART regimen and adherence history — determines viral suppression status and resistance risk
4. Medication reconciliation — extensive drug-drug interactions with ART (especially PIs and some NNRTIs via CYP3A4)
5. Symptom review by CD4 risk level — guide OI surveillance to CD4-specific thresholds
6. Nutritional status — weight, BMI, albumin; wasting is common and prognostic
7. Mental health and substance use — depression and injection drug use directly affect adherence

CD4-based risk stratification

Important — CD4 nadir effect: A patient’s lowest-ever CD4 count (the “nadir”) matters even after ART restores the count. A patient whose CD4 nadir was 20 cells/mm³ but who has recovered to 350 on ART remains at higher residual OI risk than a patient who never fell below 350, because immune reconstitution is incomplete for months to years. OI prophylaxis discontinuation thresholds (CD4 >200 for PCP prophylaxis) reflect this reality — prophylaxis is not stopped until CD4 has been durably above threshold on ART, not simply on first measurement.

Nursing interventions

Standard precautions and isolation

HIV is managed under standard precautions. HIV itself does NOT require airborne, droplet, or contact isolation. Standard precautions include:

• Gloves for contact with blood or body fluids
• Eye protection and mask when splashing is possible
• Proper sharps disposal (needleless systems where available)
• Safe handling of contaminated linens and equipment

Transmission-based precautions may apply for co-infections: a patient with HIV and active pulmonary TB requires airborne precautions (negative-pressure room, N95 respirator for all who enter — see TB nursing reference). A patient with HIV and active shingles requires contact precautions until lesions are crusted.

Needlestick and exposure protocol: PEP

A needle-stick injury or mucosal HIV exposure is a nursing emergency. The 72-hour window is non-negotiable — PEP must start within 72 hours of exposure, and earlier initiation provides better protection.

Post-exposure prophylaxis (PEP) steps:

1. Immediate wound care — flush wound with soap and water for at least 1 minute; do NOT squeeze the wound to express blood (this can increase tissue trauma without reducing viral exposure)
2. Report immediately — to supervisor, occupational health, or emergency department
3. Baseline testing — HIV antibody, hepatitis B surface antigen/antibody, hepatitis C antibody of both exposed person and source patient (if available and consented)
4. Risk assessment — occupational health or ID physician determines PEP eligibility based on exposure type (percutaneous vs mucous membrane) and source patient’s HIV status/viral load
5. Initiate PEP within 72 hours — preferred regimen: tenofovir DF/emtricitabine (Truvada) + raltegravir or dolutegravir for 28 days
6. Follow-up testing — HIV testing at baseline, 6 weeks, and 12 weeks post-exposure

PEP vs PrEP distinction (high-yield):

• PEP (post-exposure prophylaxis) — started AFTER a known or suspected exposure; 72-hour window; 28-day course; reactive/emergency use
• PrEP (pre-exposure prophylaxis) — taken BEFORE exposure by HIV-negative people at high risk; options include tenofovir DF/emtricitabine (Truvada, daily oral), tenofovir AF/emtricitabine (Descovy, daily oral), or cabotegravir injectable (every 2 months); reduces sexual transmission risk by >99% with adherence

Opportunistic infection prophylaxis

Primary OI prophylaxis is initiated at specific CD4 thresholds; it can be discontinued once CD4 count has been durably elevated on ART.

Nutrition support

Malnutrition worsens immune function and accelerates disease progression. Nutritional nursing priorities:

• Weigh at every visit; monitor BMI and mid-arm circumference
• Screen for dysphagia (esophageal candidiasis) — soft/liquid diet modification if needed
• High-calorie, high-protein diet target (35 kcal/kg/day, 1.5–2 g protein/kg/day) in patients with wasting
• Refer to registered dietitian when weight loss exceeds 5% of body weight
• Safe food handling counseling — patients with CD4 <200 should avoid raw or undercooked meat, unpasteurized products, and raw sprouts due to Salmonella, Cryptosporidium, and Listeria risk

Antiretroviral therapy (ART)

Treatment initiation: treat all, regardless of CD4

Per the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents (2023 update), ART is recommended for ALL persons living with HIV, regardless of CD4 count. This represents a shift from earlier guidelines that used CD4 thresholds to time initiation. Benefits of early treatment include:

• Reduced AIDS-defining events and non-AIDS morbidities (cardiovascular, renal, hepatic, neurocognitive)
• Prevention of transmission (U=U — see below)
• Slower CD4 decline and preservation of immune function
• Reduced systemic inflammation and immune activation

ART should be initiated at or very soon after HIV diagnosis. Rapid start (same day as diagnosis) is now recommended in most clinical settings when the patient is ready and no urgent clinical issues require evaluation first.

ART drug classes

Preferred first-line regimens (DHHS 2023)

Current DHHS guidelines favor INSTI-based regimens as first-line therapy for most adults due to high efficacy, tolerability, and high genetic barrier to resistance:

• Biktarvy (bictegravir/tenofovir AF/emtricitabine) — single-tablet once daily; preferred in most patients
• Triumeq (dolutegravir/abacavir/lamivudine) — requires HLA-B*5701 screening before use; single tablet once daily
• Dovato (dolutegravir/lamivudine) — 2-drug regimen for virologically suppressed patients or as initial therapy in selected cases

INSTI-based regimens have largely replaced PI-based regimens as first-line therapy due to better tolerability, fewer drug interactions, and superior resistance profiles. PIs remain important for treatment-experienced patients and in certain clinical scenarios.

The U=U concept: Undetectable = Untransmittable

The U=U principle, established by the PARTNER, PARTNER2, and Opposites Attract studies, is one of the most important advances in HIV care: a person with HIV who has an undetectable viral load (sustained suppression on ART) poses zero risk of sexually transmitting HIV to a partner. Key nursing communication points:

• Undetectable = viral load <200 copies/mL (most assays report this as undetectable at their lower detection limit of 20–40 copies/mL)
• U=U applies to sexual transmission — it does not eliminate needle-sharing risk, though risk is dramatically reduced
• Achieving and maintaining undetectable status requires consistent ART adherence — even brief treatment interruptions can allow viral rebound
• U=U has profound implications for patient quality of life, mental health, and relationships — it should be communicated proactively during patient education

ART adherence and resistance

HIV replication rate is approximately 10 billion virions per day without treatment, generating enormous diversity. Reverse transcriptase has no proofreading function, so mutations arise constantly. Adequate drug levels — maintained by strict adherence — suppress replication below the threshold at which resistant mutants can emerge. Subtherapeutic levels (from missed doses) allow viral replication in the presence of partial drug pressure, selecting for resistant strains. Drug resistance mutations accumulate and can render entire drug classes ineffective.

Adherence target: >95% of doses (missing more than 2–3 doses per month can compromise suppression for some regimens). Daily INSTIs such as bictegravir have a higher forgiveness threshold due to their long half-life and high genetic barrier, but the principle of consistent adherence applies to all regimens.

HIV-associated neurocognitive disorder (HAND)

Even among people with HIV who have achieved sustained viral suppression on ART, HIV-associated neurocognitive disorder (HAND) remains clinically relevant. HIV infects microglial cells and astrocytes in the CNS early in infection, and CNS viral reservoir may persist even when blood viral load is undetectable. Manifestations range from asymptomatic neurocognitive impairment (detected only on formal testing) to mild cognitive impairment (affecting everyday function) to HIV-associated dementia (now rare with ART).

Nursing assessment points for HAND:

• Screen for cognitive complaints: memory lapses, slowed processing, difficulty with complex tasks, executive dysfunction
• Distinguish from depression (often co-occurring), substance use effects, and medication side effects (efavirenz is a common cause of CNS symptoms)
• Functional impact: medication management, appointment keeping, and activities of daily living may be affected
• Refer for formal neuropsychological testing when concerns arise
• CNS-penetrating ART regimens are preferred when HAND is suspected (CNS penetration effectiveness/CPE score)

Patient education

Disclosure and stigma

HIV disclosure remains a deeply personal decision with legal and social dimensions. In many US states, intentional exposure of a partner without disclosure is criminally actionable. Nursing education priorities:

• Discuss state-specific disclosure laws — provide information without judgment
• Connect patients to social work and case management for legal guidance if needed
• Reinforce that U=U significantly changes the risk calculus and relationship dynamics
• Mental health support referral for depression, anxiety, and stigma-related distress

Safer sex and transmission prevention

• Consistent and correct condom use reduces transmission risk
• U=U: maintaining undetectable viral load eliminates sexual transmission risk
• PrEP counseling for HIV-negative partners
• Avoid sharing injection equipment; harm reduction programs, needle exchange programs, and methadone maintenance reduce transmission

Adherence support

• Use the “5 A’s” framework: Assess, Advise, Agree, Assist, Arrange follow-up
• Pill boxes, phone alarms, and pharmacy blister packs improve adherence
• Identify barriers: medication side effects, depression, substance use, food insecurity, housing instability, stigma
• Long-acting injectable ART (cabotegravir + rilpivirine, given monthly or every 2 months) is now available and preferred by some patients for whom daily oral dosing is challenging

Pregnancy and prevention of mother-to-child transmission (PMTCT)

• ART during pregnancy reduces vertical transmission risk from 15–45% (without treatment) to <1% (with ART and appropriate obstetric care)
• All pregnant people with HIV should be on ART, ideally preconception
• Preferred ART in pregnancy: INSTI-based regimens (dolutegravir safe after the first trimester; note earlier concerns about neural tube defects with first-trimester exposure)
• Mode of delivery: vaginal delivery is safe if viral load is <1,000 copies/mL at 36 weeks; cesarean section recommended for viral load >1,000 copies/mL
• Infant ART prophylaxis (zidovudine for 4 weeks) recommended for all exposed neonates regardless of maternal viral load
• Breastfeeding: in the US and resource-rich settings, formula feeding is recommended to eliminate residual transmission risk; WHO guidelines for resource-limited settings differ (ART for mother or infant during breastfeeding)

Travel considerations

• Live vaccines (MMR, varicella, yellow fever, oral typhoid) may be contraindicated at CD4 <200 — individualize per CD4 count and travel destination requirements
• Food and water safety counseling (especially Cryptosporidium, Salmonella, and traveler’s diarrhea risk at low CD4 counts)
• Medication supply: sufficient supply for trip duration plus extra; medication storage temperature requirements; customs documentation for injectable medications
• Destination-specific OI risks (e.g., histoplasmosis in Ohio/Mississippi River valleys, coccidioidomycosis in Southwest US, Penicillium marneffei in Southeast Asia)

NCLEX-style practice questions

Question 1

A nurse is caring for a patient with HIV whose most recent CD4 count is 185 cells/mm³. The patient is not currently taking OI prophylaxis. Which prophylactic medication should the nurse anticipate the provider to prescribe?

A. Azithromycin 1,200 mg once weekly B. Trimethoprim-sulfamethoxazole (TMP-SMX) 1 DS tablet daily C. Fluconazole 200 mg daily D. Clarithromycin 500 mg twice daily

Correct answer: B

Rationale: TMP-SMX prophylaxis against Pneumocystis jirovecii pneumonia (PCP) is indicated when CD4 falls below 200 cells/mm³ — this is the highest-priority OI prophylaxis threshold and a classic NCLEX question. At CD4 185, TMP-SMX is the immediate priority. Azithromycin for MAC prophylaxis (option A) and clarithromycin for MAC treatment (option D) are indicated at CD4 <50 — this patient is not yet at that threshold. Fluconazole for fungal prophylaxis (option C) is considered at CD4 <100. Knowing these CD4-based thresholds in sequence (TMP-SMX at <200; fluconazole at <100; azithromycin/MAC at <50) is essential for NCLEX and clinical practice.

Question 2

A nurse sustains a needlestick injury from a hollow-bore needle used on a patient known to be HIV-positive with a detectable viral load of 45,000 copies/mL. After washing the wound, what is the next priority action?

A. Wait 24 hours to see if signs of acute HIV syndrome develop before starting PEP B. Report the exposure and initiate PEP within 72 hours of injury C. Schedule an HIV antibody test in 3 months D. Begin a full course of TMP-SMX for 28 days

Correct answer: B

Rationale: PEP must begin within 72 hours of a high-risk exposure — the 3-day window is non-negotiable. Waiting for symptoms (option A) wastes the protective window; acute HIV syndrome appears 2–4 weeks after infection, far too late to start PEP. An HIV antibody test in 3 months (option C) is part of follow-up but is not the priority action now. TMP-SMX (option D) is for PCP prophylaxis, not HIV PEP. The preferred PEP regimen is tenofovir DF/emtricitabine plus raltegravir or dolutegravir for 28 days. Baseline HIV testing of the exposed nurse is done simultaneously but should not delay PEP initiation.

Question 3

A patient with HIV asks the nurse, “My doctor says my viral load is undetectable. Does that mean I can’t spread HIV to my partner anymore?” Which response by the nurse is most accurate?

A. “Undetectable means the virus is gone — you no longer have HIV.” B. “You still carry HIV and can still transmit it even with an undetectable viral load.” C. “When your viral load is undetectable and stays that way on your medications, you cannot sexually transmit HIV to a partner.” D. “An undetectable viral load means you should still use condoms, because the test has a margin of error.”

Correct answer: C

Rationale: This question addresses the U=U principle (Undetectable = Untransmittable), supported by landmark studies including PARTNER, PARTNER2, and Opposites Attract, which demonstrated zero linked HIV transmissions among couples where the HIV-positive partner maintained sustained viral suppression. Option A is incorrect — undetectable does not mean the virus is eliminated; HIV persists in reservoirs. Option B is inaccurate and harmful — it contradicts the evidence and can undermine the patient’s quality of life and relationships. Option D is overly cautious and inconsistent with the scientific evidence. Nurses should communicate the U=U message accurately and affirmingly.

Question 4

A patient with HIV has a CD4 count of 42 cells/mm³. The patient reports headache, low-grade fever, and mild neck stiffness over the past week. Which opportunistic infection should the nurse be most concerned about?

A. Pneumocystis jirovecii pneumonia (PCP) B. Cryptococcal meningitis C. Mycobacterium avium complex (MAC) bacteremia D. CMV colitis

Correct answer: B

Rationale: Cryptococcal meningitis classically presents with a subacute onset of fever, headache, and meningismus in patients with CD4 <100 cells/mm³ (most commonly <50). The gradual onset over days to weeks is characteristic and distinguishes it from bacterial meningitis. Diagnosis involves serum cryptococcal antigen (CrAg) and CSF India ink stain; treatment requires amphotericin B plus flucytosine induction, followed by fluconazole consolidation and maintenance. PCP (option A) presents primarily with pulmonary symptoms (dyspnea, dry cough, hypoxia). MAC (option C) presents with systemic symptoms (fever, night sweats, weight loss, diarrhea) without meningismus. CMV colitis (option D) presents with abdominal pain, bloody diarrhea, and no meningeal signs. See also the meningitis nursing reference for CSF analysis and lumbar puncture positioning.

Question 5

A provider is initiating antiretroviral therapy for a newly diagnosed patient with HIV whose CD4 count is 620 cells/mm³ and viral load is 12,000 copies/mL. The patient asks, “My immune system is still okay — do I really need to start these medications now?” Which rationale for early ART initiation is most appropriate for the nurse to explain?

A. “ART is required by law for all people diagnosed with HIV regardless of CD4 count.” B. “Starting ART early prevents your immune cells from declining and reduces your risk of transmitting HIV to others.” C. “ART is only started early because the medications are easier to tolerate when your immune system is stronger.” D. “Starting now is just a precaution in case your CD4 count drops suddenly.”

Correct answer: B

Rationale: Current DHHS guidelines recommend ART for ALL people with HIV regardless of CD4 count. The evidence-based rationale is dual: ART prevents progressive CD4 decline and AIDS-defining illnesses AND reduces transmission risk (U=U principle). The START trial demonstrated that early ART initiation (when CD4 was above 500) significantly reduced AIDS and serious non-AIDS events compared with deferred treatment. Option A is incorrect — ART is a clinical recommendation, not a legal requirement. Option C is a partial truth but not the primary rationale. Option D is inaccurate — the rationale is proactive preservation, not reactive protection.

Question 6

A nursing student studying HIV pharmacology reviews the drug class table. Which statement about integrase strand transfer inhibitors (INSTIs) is correct?

A. INSTIs require HLA-B*5701 testing before initiation to prevent hypersensitivity reactions. B. INSTIs block the CCR5 co-receptor to prevent HIV entry into CD4+ T cells. C. INSTIs are the preferred first-line drug class for most adults with HIV and have a high genetic barrier to resistance. D. INSTIs inhibit the protease enzyme, preventing viral assembly and budding.

Correct answer: C

Rationale: INSTIs (bictegravir, dolutegravir, raltegravir) are the preferred first-line drug class per DHHS guidelines for most treatment-naive adults. Bictegravir and dolutegravir have a high genetic barrier to resistance, meaning multiple mutations are required before the drugs lose efficacy — a major advantage over NNRTIs (single mutation can confer class resistance) and earlier PIs. HLA-B*5701 testing (option A) is required before abacavir (an NRTI), not INSTIs. CCR5 co-receptor blockade (option B) is the mechanism of maraviroc, an entry inhibitor. Protease enzyme inhibition (option D) is the mechanism of protease inhibitors (PIs). INSTIs specifically block the integrase enzyme, preventing viral DNA from inserting into the host genome.

Related references

• Tuberculosis nursing reference — HIV is the single greatest risk factor for TB reactivation; TB/HIV co-infection requires careful drug interaction management with ART and the RIPE regimen
• MRSA nursing reference — compare precaution types; drug-resistant infections in immunocompromised patients
• Sepsis nursing reference — septic shock in HIV patients with MAC, bacterial pneumonia, or other OIs; see Sepsis-3 criteria and 1-hour bundle
• Pneumonia nursing reference — PCP pneumonia presentation vs bacterial CAP; respiratory assessment priorities; oxygen therapy
• Meningitis nursing reference — Cryptococcal meningitis CSF findings, lumbar puncture procedure and positioning, amphotericin B monitoring
• Nursing lab values cheat sheet — CD4 count interpretation, viral load thresholds, CBC for ART-related cytopenias, LFTs for hepatotoxicity monitoring